A maker of handheld chemical detectors, 908 Devices builds tools like the MX908 that soldiers, hazmat teams, and police use to spot explosives, drugs such as fentanyl, and dangerous chemicals on the spot. Founded in Boston in 2012, the company shrank lab-grade mass spectrometry into a pocket-sized device. Its odd name comes from 0.908, the point in a mass spectrometer where founders say "the magic happens"—a fitting symbol for finding answers in unstable moments.
908 Devices issues 3,213,583 shares to satisfy RedWave earnout obligation
On July 8, 2026, 908 Devices issued 3,213,583 shares of common stock in satisfaction of Earnout Consideration under the April 29, 2024 Equity Purchase Agreement with RedWave Technology.
Show detailsHide details
The earnout was contingent on RedWave product and service revenue meeting or exceeding $37 million during the two-year period from May 1, 2024 through April 30, 2026.
The Seller Entity, CAM3 HoldCo, LLC, had the right to receive up to 4,000,000 shares of common stock under the Purchase Agreement.
The Company's obligations to issue the Earnout Consideration have been satisfied in full.
The report was filed under Item 8.01 (Other Events) to disclose the share issuance.
908 Devices holds 2026 annual meeting, elects three Class III directors and approves all proposals.
At the June 11, 2026 annual meeting, 28,653,832 shares were present, representing a 76.52% quorum of 37,446,534 outstanding shares.
Show detailsHide details
Class III directors Keith L. Crandell, Christopher Brown, and E. Kevin Hrusovsky were elected with 23,989,268, 24,120,149, and 21,164,398 votes for, respectively.
Stockholders ratified PricewaterhouseCoopers LLP as independent auditor for 2026 with 28,646,306 votes for.
The say-on-pay proposal passed with 21,187,486 votes for, and the board adopted a one-year frequency for future advisory votes.
The report was filed under Item 5.07 to disclose the final voting results of the annual meeting.
5.07 Submission of Matters to a Vote of Security Holders
908 Devices completes acquisition of NIRLAB SA for $15M headline price
908 Devices Inc. acquired all outstanding shares of NIRLAB SA and its subsidiary NIRLAB Forensics Sàrl on May 4, 2026.
Show detailsHide details
The preliminary consideration was $15 million, comprising $13 million in cash and 293,368 shares of 908 Devices common stock.
Sellers may receive up to $8 million in contingent earn-out consideration, payable in shares, based on revenue milestones by December 31, 2027.
The acquisition expands 908 Devices' narcotics detection capabilities and adds a recurring subscription model.
908 Devices also reported Q1 2026 revenue of $13.4 million, up 14% year-over-year, and raised its 2026 revenue outlook to $67-70 million.
1.01 Entry into a Material Definitive Agreement · 2.01 Completion of Acquisition or Disposition of Assets · 2.02 Results of Operations and Financial Condition · 3.02 Unregistered Sales of Equity Securities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
908 Devices reports Q3 2025 revenue of $14.0M, down 4% YoY, and reiterates 2025 revenue outlook of $54M-$56M
Third quarter 2025 revenue was $14.0 million, a 4% decrease year over year, with recurring revenue of $4.8 million (35% of total revenue).
Show detailsHide details
Adjusted EBITDA loss improved 53% quarter over quarter to $1.8 million, and adjusted gross margin was 58%, up 190 basis points quarter over quarter.
Net loss from continuing operations was $14.9 million for Q3 2025, compared to $23.6 million in Q3 2024.
Cash, cash equivalents and marketable securities were $112.1 million as of September 30, 2025, with no debt outstanding.
The company reiterated full-year 2025 revenue guidance from continuing operations of $54.0 million to $56.0 million, representing 13% to 17% growth over 2024.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits